The Virtuoso Surgical Robotic System received FDA breakthrough designation for bladder lesion removal, enabling expedited development and review processes. En bloc resection improves cancer staging ...
FG-3246 targets CD46 in mCRPC patients, focusing on those who progressed on ARSI without prior taxane therapy. The trial will evaluate FG-3246's safety, efficacy, and pharmacokinetics, alongside ...
Fosnight described how stigma itself becomes a barrier to care, even though effective diagnostic and treatment options are available. In an interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, ...
Take a look through the key trials investigating BCG/ICI combinations in BCG-naïve NMIBC. In BCG-naïve non–muscle invasive bladder cancer (NMIBC), emerging options are largely focused on combining BCG ...
BioTraceIO360 received FDA 510(k) clearance for kidney ablation, expanding its previous liver tumor ablation indication. The platform standardizes minimally invasive care, enhancing treatment planning ...
The FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years or older. Recommended dosages are 395 mg/4800 U every 3 weeks or 790 mg/9600 U every 6 ...
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback